Drug Research
Catalent and Exelixis Enter into Collaboration, License, and Exclusive Option Agreement to Develop ADC Leveraging SMARTag Bioconjugation Technology
Exelixis, Inc. and Catalent announced a partnership under which Catalent’s Redwood Bioscience subsidiary will develop multiple antibody-drug conjugates (ADCs) for Exelixis using Catalent’s proprietary...
Clinical Trials
Sharp launches Clinventory Inventory Management System (IMS) for clinical trials
Sharp - part of UDG Healthcare plc, a global leader in contract packaging clinical supply services, has launched a new Inventory Management System (IMS)...
News
China shows off Covid-19 vaccines for first time
China has put its homegrown coronavirus vaccines on display for the first time, as the country where the contagion was discovered looks to shape...
Clinical Trials
Sinovac Biotech’s COVID-19 vaccine enters phase 3 trial globally
A COVID-19 vaccine candidate developed by Beijing-based Sinovac Life Sciences Corp has obtained preliminary approval in Bangladesh for entering phase III clinical trials, the...
News
ADMA Biologics Highlights Launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA Assay to Detect SARS-CoV-2 Neutralizing Antibodies in Plasma
ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the launch of COVID-19 ImmunoRank...
News
UNICEF to lead procurement and supply of COVID-19 vaccines in world’s largest and fastest ever operation of its kind
UNICEF is leading efforts to procure and supply COVID-19 vaccines in what could possibly be the world’s largest and fastest ever procurement and supply...
News
Mesoblast Limited receives ethics approval to treat COVID-19 patients in Australia
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that it has received ethics approval to include Australian hospitals in thePhase...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read